ERR2208902
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ADIPOGENESIS+0.300
- MYC_TARGETS_V2+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- PEROXISOME+0.300
- CHOLESTEROL_HOMEOSTASIS+0.200
- FATTY_ACID_METABOLISM+0.200
- ANGIOGENESIS+0.100
- BILE_ACID_METABOLISM+0.100
- DNA_REPAIR+0.100
- MTORC1_SIGNALING+0.100
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.300
- TGF_BETA_SIGNALING-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- ALLOGRAFT_REJECTION-0.200
- APICAL_SURFACE-0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
- HYPOXIA-0.200
- IL6_JAK_STAT3_SIGNALING-0.200
- INFLAMMATORY_RESPONSE-0.200
- INTERFERON_ALPHA_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f844415e-ca2a-4837-b050-06775fdb2ed5 | — | — | 0.791 |
| 2 | TCGA-A2-A3XV-01A-21R-A239-07 | — | B | 0.786 |
| 3 | MNG265 | — | — | 0.778 |
| 4 | e84aa97b-e429-4994-acef-2b57be71fe9a | — | — | 0.776 |
| 5 | d22c9285-50cf-4724-9f81-606fb54c00fc | — | — | 0.770 |
| 6 | TCGA-D8-A1JS-01A-11R-A13Q-07 | — | B | 0.757 |
| 7 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.750 |
| 8 | C3N-01024 | — | cohortA1 | 0.743 |
| 9 | TCGA-LL-A6FP-01A-11R-A31O-07 | — | B | 0.742 |
| 10 | MNG1094 | — | — | 0.740 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |